SUPN
NEUTRAL
$51.39
Live
Supernus Pharmaceuticals, Inc. · NASDAQ
Target $63.17
(+22.9%)
$29.16
52W Range
$59.68
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$2.96B
P/E
N/A
ROE
-3.7%
Profit margin
-5.4%
Debt/Equity
0.04
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
SUPN presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 and bearish insider sentiment (30/100). Despite these fundamental warnings, the company shows strong top-line growth (21.5% YoY) and maintains a very low debt-to-equity ratio of 0.04. Analysts remain highly optimistic with a 'Strong Buy' consensus and a target price of $63.17, suggesting a disconnect between current operational health and future growth expectations. The stock is currently a speculative play where strong revenue growth is fighting against deteriorating fundamental health metrics.
Key Strengths
Strong revenue growth of 21.50% YoY
Very low leverage with a Debt/Equity ratio of 0.04
High Gross Margin of 89.63%
Strong analyst consensus (Strong Buy) with significant upside to target price
Healthy liquidity with a Current Ratio of 1.91
Key Risks
Weak fundamental health indicated by a Piotroski F-Score of 2/9
Negative operating margins (-28.90%) indicating inefficiency
Heavy insider selling totaling $9.00M in the last 6 months
Highly volatile quarterly earnings track record
Bearish technical trend (0/100)
AI Fair Value Estimate
Based on comprehensive analysis
$58.0
+12.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
41
Moderate
60
75
50
20
0
AI Verdict
Speculative / High Risk
Key drivers: Revenue Growth, Piotroski F-Score, Insider Selling, Low Debt
Confidence
80%
Value
60/100
Trades at a low forward multiple relative to growth, but lacks a Graham Number for defensive valuation.
Positives
- Attractive Forward P/E of 12.18
Watchpoints
- Price/Book of 2.78 is elevated
- Negative current profit margins
Future
75/100
Growth rates are strong, but translation to consistent net income is lagging.
Positives
- 21.5% YoY Revenue growth
- Strong analyst price targets ($63.17)
Watchpoints
- Earnings volatility
Past
50/100
Price performance has been strong, but fundamental trends are declining.
Positives
- Strong 1Y price return (+67.1%)
Watchpoints
- Inconsistent earnings surprises
Health
20/100
While solvent, the F-Score suggests a deterioration in operational efficiency and profitability.
Positives
- Low Debt/Equity
- Good Current Ratio
Watchpoints
- Piotroski F-Score of 2/9 indicates weak financial health trends
Dividend
0/100
Non-dividend paying growth stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$51.39
Analyst Target
$63.17
Upside/Downside
+22.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SUPN and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
Primary
|
+66.0% | +41.6% | +67.1% | +2.4% | +4.3% | +1.4% |
|
PRVA
Privia Health Group, Inc.
Peer
|
+4.4% | -7.2% | +1.4% | -5.9% | +11.3% | +7.4% |
|
BKD
Brookdale Senior Living Inc.
Peer
|
+153.4% | +367.5% | +163.2% | +72.4% | +18.9% | +6.2% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
|
ICUI
ICU Medical, Inc.
Peer
|
-38.8% | -28.3% | -9.2% | +10.1% | -6.0% | +1.9% |
SUP
Supernus Pharmaceuticals, Inc.
Primary
5Y
+66.0%
3Y
+41.6%
1Y
+67.1%
6M
+2.4%
1M
+4.3%
1W
+1.4%
PRV
Privia Health Group, Inc.
Peer
5Y
+4.4%
3Y
-7.2%
1Y
+1.4%
6M
-5.9%
1M
+11.3%
1W
+7.4%
BKD
Brookdale Senior Living Inc.
Peer
5Y
+153.4%
3Y
+367.5%
1Y
+163.2%
6M
+72.4%
1M
+18.9%
1W
+6.2%
ARQ
Arcutis Biotherapeutics, Inc.
Peer
5Y
-30.1%
3Y
+98.3%
1Y
+53.6%
6M
+31.6%
1M
-14.4%
1W
-5.2%
ICU
ICU Medical, Inc.
Peer
5Y
-38.8%
3Y
-28.3%
1Y
-9.2%
6M
+10.1%
1M
-6.0%
1W
+1.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
12.18
PEG Ratio
N/A
P/B Ratio
2.78
P/S Ratio
4.12
EV/Revenue
3.74
EV/EBITDA
60.62
Market Cap
$2.96B
Profitability
Profit margins and return metrics
Profit Margin
-5.36%
Operating Margin
-28.9%
Gross Margin
89.63%
ROE
-3.68%
ROA
-2.09%
Growth
Revenue and earnings growth rates
Revenue Growth
+21.5%
Earnings Growth
N/A
Q/Q Revenue Growth
+21.48%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.04
Low debt
Current Ratio
1.91
Good
Quick Ratio
1.47
Good
Cash/Share
$5.36
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
89.1%
Op. Margin
6.5%
Net Margin
-1.9%
Total Assets
$1.5B
Liabilities
$0.4B
Equity
$1.1B
Debt/Equity
0.37x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
98%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$0.88
+215.0% surprise
2025-11-04
$-0.8
-900.0% surprise
2025-08-05
$0.4
+731.6% surprise
Healthcare Sector Comparison
Comparing SUPN against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-3.68%
This Stock
vs
-97.91%
Sector Avg
-96.2%
(Below Avg)
Profit Margin
-5.36%
This Stock
vs
-16.16%
Sector Avg
-66.8%
(Weaker)
Debt to Equity
0.04
This Stock
vs
3.0
Sector Avg
-98.7%
(Less Debt)
Revenue Growth
21.5%
This Stock
vs
142.9%
Sector Avg
-85.0%
(Slower)
Current Ratio
1.91
This Stock
vs
4.65
Sector Avg
-59.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
NEUTRAL | $2.96B | - | -3.7% | -5.4% | $51.39 | |
|
PRVA
Privia Health Group, Inc.
|
NEUTRAL | $3.02B | 126.42 | 4.0% | 1.1% | $24.02 | Compare |
|
BKD
Brookdale Senior Living Inc.
|
BEARISH | $3.08B | - | -212.3% | -9.9% | $12.95 | Compare |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | Compare |
|
ICUI
ICU Medical, Inc.
|
BEARISH | $3.14B | 4189.33 | 0.0% | 0.0% | $125.68 | Compare |
SUPN
Supernus...
NEUTRAL
Mkt Cap
$3.0B
P/E
-
ROE
-3.7%
Price
$51.39
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-18 | BHATT PADMANABH P | Officer | Sale | 107,250 | $5,388,432 |
| 2026-03-18 | BHATT PADMANABH P | Officer | Option Exercise | 107,250 | $3,892,392 |
| 2026-03-13 | KHATTAR JACK A | Chief Executive Officer | Sale | 35,000 | $1,763,124 |
| 2026-03-12 | HUDSON FREDERICK M | Director | Sale | 5,369 | $271,725 |
| 2026-03-10 | HORICH WILLIAM TODD | Officer | Sale | 8,877 | $483,797 |
| 2026-03-09 | MOTTOLA FRANK | Chief Operating Officer | Sale | 1,623 | $87,074 |
| 2026-03-06 | MOTTOLA FRANK | Chief Operating Officer | Stock Award | 3,750 | - |
| 2026-03-06 | HORICH WILLIAM TODD | Officer | Stock Award | 7,500 | - |
| 2026-03-06 | KHATTAR JACK A | Chief Executive Officer | Stock Award | 38,640 | - |
| 2026-03-06 | DEC TIMOTHY C | Chief Financial Officer | Stock Award | 6,000 | - |
| 2026-03-06 | GEMAYEL GEORGES PH.D. | Director | Sale | 18,787 | $1,002,811 |
| 2026-03-06 | GEMAYEL GEORGES PH.D. | Director | Option Exercise | 7,905 | $199,996 |
| 2026-02-25 | MOTTOLA FRANK | Chief Operating Officer | Stock Award | 1,875 | - |
| 2026-02-25 | RUBIN JONATHAN | Officer | Stock Award | 1,250 | - |
| 2026-02-25 | DEC TIMOTHY C | Chief Financial Officer | Stock Award | 2,500 | - |
BHATT PADMANABH P
Officer
2026-03-18
107,250 shares
·
$5,388,432
BHATT PADMANABH P
Officer
2026-03-18
107,250 shares
·
$3,892,392
KHATTAR JACK A
Chief Executive Officer
2026-03-13
35,000 shares
·
$1,763,124
HUDSON FREDERICK M
Director
2026-03-12
5,369 shares
·
$271,725
HORICH WILLIAM TODD
Officer
2026-03-10
8,877 shares
·
$483,797
MOTTOLA FRANK
Chief Operating Officer
2026-03-09
1,623 shares
·
$87,074
MOTTOLA FRANK
Chief Operating Officer
2026-03-06
3,750 shares
HORICH WILLIAM TODD
Officer
2026-03-06
7,500 shares
KHATTAR JACK A
Chief Executive Officer
2026-03-06
38,640 shares
DEC TIMOTHY C
Chief Financial Officer
2026-03-06
6,000 shares
GEMAYEL GEORGES PH.D.
Director
2026-03-06
18,787 shares
·
$1,002,811
GEMAYEL GEORGES PH.D.
Director
2026-03-06
7,905 shares
·
$199,996
MOTTOLA FRANK
Chief Operating Officer
2026-02-25
1,875 shares
RUBIN JONATHAN
Officer
2026-02-25
1,250 shares
DEC TIMOTHY C
Chief Financial Officer
2026-02-25
2,500 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
6 analysts
Stifel
2025-12-19
Hold
Hold
B of A Securities
2025-10-29
Buy
TD Cowen
2025-10-23
Buy
Buy
Past News Coverage
Recent headlines mentioning SUPN from our newsroom.
Newest → oldest
No matching news yet.